🚀 Exciting News! 🚀 We're thrilled to announce that first patients have been recruited to VISION - our observational study aimed at transforming the treatment of early triple-negative breast cancer (TNBC)! VISION will not only identify biomarkers of therapy response but also enhance the precision of therapeutic predictions for individual patients using Concr’s cutting-edge FarrSight®-Twin alongside standard diagnostic tests. 🤝 AI-VISION: A synergistic collaboration This multi-disciplinary initiative brings together the expertise of Concr, The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, and Durham University. Funded by Innovate UK, AI-VISION leverages the power of multi-modal data and Concr’s proprietary Bayesian frameworks to uncover innovative treatment pathways for TNBC. 🌟 Why this matters TNBC is an aggressive cancer and an alarming 40% of women die within 5 years of their initial cancer diagnosis. More reliable biomarkers and novel approaches to treatment stratification offer hope to significantly improve survival. This study is also set to contribute to the body of evidence supporting the efficacy and safety of advanced computational methods in enabling precision medicine, ultimately aiming to improve patient outcomes. Read the full press release here: https://lnkd.in/eBgbTEtu And stay tuned for updates as we embark on this journey to transform TNBC care! #TechBio #Oncology #TNBC #BreastCancer #DigitalTwin #ClinicalTrials #AI #PrecisionMedicine #FromCosmologyToOncology
Concr
Biotechnology Research
London, England 905 followers
Solving data to enable precision therapy for all
About us
Concr is a techbio company providing predictive modelling solutions to enhance confidence and foresight about therapeutic efficacy of existing and emerging cancer drugs. By accurately predicting response for individual patients and cohorts, we enable more efficacious and informative trials, thereby improving probability of success of novel cancer therapeutics. Our Farr-Sight® platform, built on decades of astrophysics research, models diverse data interactions to simulate human disease biology, enabling accurate predictions with minimal data. This is especially valuable in early-stage trials and rare cancers. Validated through collaborations with Roche, Step Pharma, The Institute of Cancer Research, The Christie NHS Foundation Trust, Durham University, and The University of Queensland, our solutions are trusted by researchers in industry, academia and healthcare. Concr’s investors include the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Debiopharm, Cambridge Angels, Parkwalk Advisors, Deep Science Ventures and SyndicateRoom. The company has also received a grant from Innovate UK to trial Concr’s technology for improving treatment decision-making in clinic. The company’s HQ is in London, England, with a wholly owned subsidiary in Brisbane, Australia.
- Website
-
http://www.concr.co
External link for Concr
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- London, England
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Biotechnology, Precision Medicine, Oncology Research, Drug Development, Machine Learning, and Statistical Modelling
Locations
-
Primary
Get directions
London, England, GB
-
Get directions
308 Queen St
Brisbane City, Queensland 4000, AU
Employees at Concr
-
Amber Johns
Global Oncology Research and Development, International Cancer Genome Consortium
-
Matthew Griffiths
Co-Founder at ConcR
-
Aidan Kubeyev, PhD
Driven Scientist: Machine Learning, Data Science, Computational Physics, Biotech
-
Uzma Asghar
Consultant Medical Oncologist (The Royal Marsden NHS Foundation Trust); Chief Scientific Officer (Concr LTD)
Updates
-
Here's your chance to get to know our CEO Irina Babina and her path that led her to Concr! 👇 Great many thanks to WiSB - Women in Synthetic Biology 🙏 SynBioBeta Industrial Biotechnology Innovation Centre #WomeninSTEM #syntheticbiology #engineeringbiology #innovation
WiSB Women’s Hour – In conversation with Dr Irina Babina, Concr Join us to hear Irina talk about her non-linear career and how her wide-ranging experience prepared her for leadership, and about the transition from science to business. Irina trained as a geneticist and spent 10 years as a cancer scientist before turning to funding management and investing to help other researchers develop their healthcare innovations. Ultimately, this ambition led to Concr, a techbio company that applies astrophysics computational models to model human biology in silico and solve translational challenges in cancer treatment and care. Irina succeeded founder-CEO in January 2024. It's sure to be an inspiring and insightful conversation! 📆17 July 2024, 4:00 pm 5:00 pm 🎟️https://lnkd.in/ezwc3spx SynBioBeta Potter Clarkson Sara Holland Liz Fletcher #syntheticbiology #engineeringbiology #womeninSTEM #womeninsyntheticbiology BioIndustry Association (BIA) Scottish Enterprise Industrial Biotechnology Innovation Centre
-
-
Concr reposted this
📣 Startup Spotlights 📣 We are excited to have Concr, Constructive Bio, Engimmune Therapeutics, Gigabases, Neobe Therapeutics and Xterna presenting at the Synthetic & Engineering Biology British-Swiss Summit on 📅 22 May at the 📍 M Shed Bristol. ➡ Register now to secure your space: https://lnkd.in/dvAnmJJn #engineeringbiology #syntheticbiology #biotech #innovation Jointly organised by the Bristol BioDesign Institute, Swiss Business Hub UK, BioIndustry Association (BIA) and Lucideon, and followed by networking at Science Creates.
-
-
Concr reposted this
This one came around quickly! Looking forward to #LSXWorld next week - give me a shout if you're attending 👋 🗓 29-30th April 2024 📍 London, UK LSX - partnering for Life Science eXecutives Concr #Partnering #Capital #Strategy #FromCosmologyToOncology
-
-
Thank you for the #feature, Cambridge Enterprise, and for the unwavering support of Concr 🤝 Delighted to have you in our corner and to be a part of such an innovate portfolio! #innovation #partnership #lifesciences Loukik Arora, Ph.D. Christine Martin Lexi Radcliffe-Hart Founders at the University of Cambridge University of Cambridge
Having had another very successful year supporting our researchers, entrepreneurs, founders and portfolio companies in delivering global impact from the incredible research within the University of Cambridge, now is the time to reflect and celebrate. We have seen growth in both our existing areas and the introduction of new initiatives to further enhance the support available to University innovation. In our 2023 Annual Review, you can explore the stories behind the innovation (including features on Aspuna Group, Concr, Colorifix, Nu Quantum and T-Therapeutics Ltd), where our ambitions will take us next, as well as understanding how we supported 2,399 researchers and distributed £21.7 million to the University in 2022-2023. Read the Annual Review 2023 here: https://bit.ly/3UkWHpL #AnnualReview #AnnualReport #Innovation #Partnership #Impact Founders at the University of Cambridge, Ceres Agri-Tech Knowledge Exchange Partnership, Cambridge Innovation Capital, ideaSpace, TenU
-
📣 Partnering is now open! Book a 1:1 meeting with our CEO Irina Babina to learn how Concr can increase success of your drug asset with our best therapeutic response predictions yet 🎯 Plus, view the demo of our translational analytics platform FarrSight® and learn about our most recent advancements in #modelling human biology and #biomarker identification 🚀 🗓 29-30th April 2024 📍 London, UK LSX - partnering for Life Science eXecutives https://concr.co/contact #LSXWorld #Partnering #Capital #Strategy #FromCosmologyToOncology
-
-
Today we're back to where it all began 👨🎓 Our esteemed co-founder and CTO Dr Matthew Griffiths will be returning to Cambridge Enterprise, to talk about Concr's progress and plans for the future. You can catch him in Cambridge today, and in the meantime, read about the origins of the technology behind Concr's predictive analytics that sprouted in the Cambridge ecosystem: https://lnkd.in/edkSkQkE #techbio #precisiononcology #FromCosmologyToOncology
-
-
Next week! Come and meet our CEO Irina Babina at the Hello Tomorrow Global Challenge, and watch her pitch as one of the finalists in the Digital Health and Medical Device track. 📍 Paris, France 📅 20-22 March 2024 #techbio #deeptech #startups #FromCosmologytoOncology
-
-
Concr reposted this
🏆 Breaking news: the shortlist for our Innovation and Entrepreneurship Awards 2024 is out! Congratulations, everyone! We can’t wait to celebrate your achievements at the Awards Ceremony on 20 March. Anaid Benitez, Faith Nutter Howard, Mara Artibani, Matt De Vries, Tiffany S. Ma, DPhil (PhD), Ioannis Prattis, PhD, Andrew Baker, Meysam Keshavarz, Robert Bentham, Marcos Burger Ramos, Felipe Galvez-Cancino, Monika Gullerova, Maike Heffner-de la Roche, Kevin Litchfield, Richard Mair, Harveer Dev, Santiago Zelenay, Kevin Myant, Dan Woodcock, Salim Khakoo, Maria Giovanna Lizio, Cherry NY CHIA, Maya Thanou, Liisi Laaniste, Bakul Gupta, PhD, Irina Babina, Myriam Ouberai, Ishani Malhotra, Pahini Pandya, Annelise Soulier, Ana Gomes, Ljiljana Fruk, Uzma Asghar, Laura Towart, Apollo Imperial Hospitals, Apeikon Therapeutics, UCL, The University of Edinburgh, Neobe Therapeutics Barts Cancer Institute (Queen Mary University of London) #IEAwards2024
-
Concr reposted this
👀 EXCITING #AI NEWS FROM THE ICR 👀 We’re involved in a new, trans-national, AI-powered collaboration that could help improve clinical decision making for cancer patients. This could; ➡️ Guide the use of immunotherapy to breast cancer patients who could significantly benefit from it ➡️ Support doctors in treating patients more effectively ➡️ Demonstrate the safety of new computational methods to deliver precision cancer treatment Other interesting points; ➡️ The collaboration involved academic and industry researchers from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, cosmologists from Durham University, and Techbio company Concr ➡️ It was made possible thanks to a new grant of almost £800,000 from Innovate UK, who provide funding for innovative collaborative research To read the full article, please visit: https://bitly.ws/3cYTD #AI #aipowered #aipoweredscience #aiscience #artificalintelligence #breastcancer #helpingcancerpatients #defeatcancer #aiadvancements #TheRoyalMarsden #DurhamUniversity #Concr #InnovateUK #innovation
New AI collaboration could advance precision therapy in breast cancer
icr.ac.uk